ET-901 / EdiGene - LARVOL DELTA

EDI-901-SLE01: A Study to Evaluate the Safety and Efficacy of ATHENA CAR-T in Subjects With Systemic Lupus Erythematosus (clinicaltrials.gov) - P1 | N=12 | Not yet recruiting | Sponsor: EdiGene Inc. | Initiation date: Apr 2024 ➔ Jul 2024

Trial initiation date • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus • IFNG • TNFA

A Study to Evaluate the Safety and Efficacy of ATHENA CAR-T in Subjects With Systemic Lupus Erythematosus (clinicaltrials.gov) - P1 | N=12 | Recruiting | Sponsor: EdiGene Inc.

New P1 trial • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus • IFNG • TNFA

TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-NHL (clinicaltrials.gov) - P1/2 | N=30 | Recruiting | Sponsor: Chinese PLA General Hospital | Not yet recruiting ➔ Recruiting

CAR T-Cell Therapy • Enrollment open • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • BCL2 • BCL6 • CCND1 • IL10 • IL2 • IL6 • TNFA

TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-NHL (clinicaltrials.gov) - P1 | N=18 | Not yet recruiting | Sponsor: Chinese PLA General Hospital

CAR T-Cell Therapy • New P1 trial • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • BCL2 • BCL6 • CCND1 • IL10 • IL2 • IL6 • TNFA